Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 5Unknown 3Recruiting 3Terminated 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 282Carcinoma, Non-Small-Cell Lung 253Leukemia, Myeloid, Acute 190Breast Neoplasms 153Melanoma 151Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 114Lymphoma 113Leukemia, Lymphocytic, Chronic, B-Cell 108Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 86Prostatic Neoplasms 83Lung Neoplasms 82Lymphoma, Large B-Cell, Diffuse 77Squamous Cell Carcinoma of Head and Neck 76Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 68Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Stomach Neoplasms 52Head and Neck Neoplasms 52Triple Negative Breast Neoplasms 51

Interventions

camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Advanced Tumors × Clear all
NCT05799183 2024-12-31

A SHR-1210 BE Study on Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
12 enrolled

Advanced Tumors

NCT05068856 2024-07-18

A Study of HRS2543 in Patients With Advanced Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1 Terminated
10 enrolled

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡